In:
The Journal of Immunology, The American Association of Immunologists, Vol. 190, No. 1_Supplement ( 2013-05-01), p. 170.35-170.35
Abstract:
Background: Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan (TRP) into kynurenine (KYN), driving the development, stabilization and activation of regulatory T cells, and suppressing anti-tumor T-cell responses. Patients and methods: We investigated IDO1 expression and function in 22 children with acute myeloid leukemia (AML; median age at diagnosis: 8 years, range 1-16). IDO expression was assessed with Western blotting; TRP and KYN levels were measured with RP-HPLC. Results: Leukemia blasts from 10 out of 21 evaluable AML cases up-regulated IDO1 expression and function after in vitro challenge with IFN-γ, as indicated by higher KYN levels in supernatants of stimulated (24.3 μM/L, range 10.8-37.7) compared with unstimulated AML cells (1.3 μM/L, 0.9-2.7; p=0.0022). IDO induction was abrogated by STAT3 inhibitors; furthermore, co-immuno-precipitation assays suggested the occurrence of physical interactions between IDO and STAT3 in leukemia cells. IDO-expressing AML blasts restrained Th1 cytokine production by allogeneic CD8+ T cells, an effect that was partially abrogated by D,L-1-methyl-tryptophan, an IDO inhibitor. A Kaplan-Meier estimate of the 3-year overall survival indicated a clear benefit for IDO- AML cases compared with IDO+ ones (68% versus 33%). Conclusions: Blast cells from childhood AML express functional IDO1. From a therapeutic standpoint, interference with IDO1 activity may restore anti-leukemia Th1 immune responses and improve disease outcome.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.190.Supp.170.35
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2013
detail.hit.zdb_id:
1475085-5
Permalink
